Insight Molecular Diagnostics Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net revenue | $32 | $2,138 |
| Cost of revenues | 17 | 813 |
| Gross profit | 15 | 1,325 |
| Operating expenses: | ||
| Research and development | 4,953 | 2,924 |
| Sales and marketing | 2,402 | 1,206 |
| General and administrative | 2,991 | 3,115 |
| Change in fair value of contingent consideration | (5,918) | 879 |
| Total operating expenses | 4,428 | 8,124 |
| Loss from operations | (4,413) | (6,799) |
| Other (expenses) income: | ||
| Interest expense | (23) | (29) |
| Other income, net | 146 | 157 |
| Total other income, net | 123 | 128 |
| Loss before income taxes | (4,290) | (6,671) |
| Income taxes | — | — |
| Net loss | $(4,290) | $(6,671) |
| Net loss per share: | ||
| Net loss per share - basic and diluted | $(0.12) | $(0.26) |
| Weighted average shares outstanding - basic and diluted | 34,519 | 25,694 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.